Zydus Lifesciences Limited has informed the Exchange about press release dated 31-Aug-2022 titled Zydus receives two final approvals from the USFDA for Venlafaxine Extended-Release Tablets and Pregabalin Extended-Release Tablets
Press Release Aug 31 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing the receipt of final approvals from the USFDA for two medications: Venlafaxine Extended-Release Tablets and Pregabalin Extended-Release Tablets. The press release details the uses of these medications, including treatment for depression and nerve pain, and mentions their expected manufacturing location in Ahmedabad, India. Additionally, the release highlights the annual sales figures for both drugs in the United States, indicating their market potential.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 30 2022
- Press Release Aug 11 2022
- Press Release Aug 05 2022
- Press Release Aug 04 2022
- Press Release Jul 26 2022
Later from Zydus Lifesciences
- Press Release Sep 07 2022
- Press Release Sep 09 2022
- Press Release Sep 12 2022
- Press Release Sep 13 2022
- Press Release Sep 16 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences